0.18
-0.0076(-4.00%)
Currency In USD
| Previous Close | 0.19 |
| Open | 0.18 |
| Day High | 0.19 |
| Day Low | 0.18 |
| 52-Week High | 1.49 |
| 52-Week Low | 0.16 |
| Volume | 3.4M |
| Average Volume | 1.86M |
| Market Cap | 15.75M |
| PE | -0.18 |
| EPS | -1 |
| Moving Average 50 Days | 0.22 |
| Moving Average 200 Days | 0.36 |
| Change | -0.01 |
If you invested $1000 in Beyond Air, Inc. (XAIR) since IPO date, it would be worth $61.83 as of June 01, 2025 at a share price of $0.182. Whereas If you bought $1000 worth of Beyond Air, Inc. (XAIR) shares 5 years ago, it would be worth $25.69 as of June 01, 2025 at a share price of $0.182.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GlobeNewswire Inc.
Apr 24, 2025 8:05 PM GMT
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
GlobeNewswire Inc.
Apr 21, 2025 8:05 PM GMT
The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2